Phospho-p53 (Thr18) Antibody

Phospho-p53 (Thr18) Antibody

收藏
  • 询价
  • Cell Signaling Technology已认证
  • USA
  • 2025年12月10日
  • W
  • Rabbit
  • H
avatar
品牌商
12钻石会员
  • 企业认证

    • 详细信息
    • 技术资料
    • 抗体英文名

      Phospho-p53 (Thr18) Antibody

    • 抗原

      synthetic phosphopeptide corresponding to residues surrounding Thr18 of human p53

    • 应用范围

      W

    • 宿主

      Rabbit

    • 保质期

      详见说明书

    • 库存

      大量

    • 级别

      详见MSDS文件

    • 供应商

      CST

    • 适应物种

      H

    • 是否单克隆

      2

    • 保存条件

      -20°c

    • 规格

      100 ul (10 western blots)/carrier free & custom formulation / quantity

    规格:产品价格:¥请询价
    规格:100 ul (10 western blots)产品价格:¥请询价
    规格:carrier free & custom formulation / quantity产品价格:¥请询价

    pathway more info application references datasheet PDF MSDS PDF protocols

    Applications Key:  W=Western Blotting
    Reactivity Key:  H=Human
    Species cross-reactivity is determined by western blot. Species enclosed in parentheses are predicted to react based on 100% sequence homology.

    Applications Reactivity Sensitivity MW (kDa) Source
    W H Endogenous 53 Rabbit
    Protocols
    Specificity / Sensitivity

    Phospho-p53 (Thr18) Antibody detects endogenous levels of p53 only when phosphorylated at threonine 18.

    Source / Purification

    Polyclonal antibodies are produced by immunizing animals with a synthetic phosphopeptide corresponding to residues surrounding Thr18 of human p53. Antibodies are purified by protein A and peptide affinity chromatography.

    Western Blotting

    Western Blotting

    Western blot analysis of extracts from MCF-7 cells treated with doxorubicin (0.5 uM, 24 h) or doxorubicin plus lambda Phosphatase NEB#P0753 (10,000 Units/ml, 1h), using Phospho-p53 (Thr18) Antibody (upper) or p53 Antibody #9282 (lower).

    Background

    The p53 tumor suppressor protein plays a major role in cellular response to DNA damage and other genomic aberrations. Activation of p53 can lead to either cell cycle arrest and DNA repair or apoptosis (1). p53 is phosphorylated at multiple sites in vivo and by several different protein kinases in vitro (2,3). DNA damage induces phosphorylation of p53 at Ser15 and Ser20 and leads to a reduced interaction between p53 and its negative regulator, the oncoprotein MDM2 (4). MDM2 inhibits p53 accumulation by targeting it for ubiquitination and proteasomal degradation (5,6). p53 can be phosphorylated by ATM, ATR, and DNA-PK at Ser15 and Ser37. Phosphorylation impairs the ability of MDM2 to bind p53, promoting both the accumulation and activation of p53 in response to DNA damage (4,7). Chk2 and Chk1 can phosphorylate p53 at Ser20, enhancing its tetramerization, stability, and activity (8,9). p53 is phosphorylated at Ser392 in vivo (10,11) and by CAK in vitro (11). Phosphorylation of p53 at Ser392 is increased in human tumors (12) and has been reported to influence the growth suppressor function, DNA binding, and transcriptional activation of p53 (10,13,14). p53 is phosphorylated at Ser6 and Ser9 by CK1δ and CK1ε both in vitro and in vivo (13,15). Phosphorylation of p53 at Ser46 regulates the ability of p53 to induce apoptosis (16). Acetylation of p53 is mediated by p300 and CBP acetyltransferases. Inhibition of deacetylation suppressing MDM2 from recruiting HDAC1 complex by p19 (ARF) stabilizes p53. Acetylation appears to play a positive role in the accumulation of p53 protein in stress response (17). Following DNA damage, human p53 becomes acetylated at Lys382 (Lys379 in mouse) in vivo to enhance p53-DNA binding (18). Deacetylation of p53 occurs through interaction with the SIRT1 protein, a deacetylase that may be involved in cellular aging and the DNA damage response (19).

    Phosphorylation of p53 at Thr18 by casein kinase 1 has been reported to disrupt p53-MDM2 binding, but phosphorylation at this site requires prior phosphorylation at Ser15 (17,18).

    1. Levine, A.J. (1997) Cell 88, 323-331.
    2. Meek, D.W. (1994) Semin. Cancer Biol. 5, 203-210.
    3. Milczarek, G.J. et al. (1997) Life Sci. 60, 1-11.
    4. Shieh, S.Y. et al. (1997) Cell 91, 325-334.
    5. Chehab, N.H. et al. (1999) Proc. Natl. Acad. Sci. USA 96, 13777-13782.
    6. Honda, R. et al. (1997) FEBS Lett. 420, 25-27.
    7. Tibbetts, R.S. et al. (1999) Genes Dev. 13, 152-157.
    8. Shieh, S.Y. et al. (1999) EMBO J. 18, 1815-1823.
    9. Hirao, A. et al. (2000) Science 287, 1824-1827.
    10. Hao, M. et al. (1996) J. Biol. Chem. 271, 29380-29385.
    11. Lu, H. et al. (1997) Mol. Cell. Biol. 17, 5923-5934.
    12. Ullrich, S.J. et al. (1993) Proc. Natl. Acad. Sci. USA 90, 5954-5958.
    13. Kohn, K.W. (1999) Mol. Biol. Cell 10, 2703-2734.
    14. Lohrum, M. and Scheidtmann, K.H. (1996) Oncogene 13, 2527-2539.
    15. Knippschild, U. et al. (1997) Oncogene 15, 1727-1736.
    16. Oda, K. et al. (2000) Cell 102, 849-862.
    17. Ito, A. et al. (2001) EMBO J. 20, 1331-1340.
    18. Sakaguchi, K. et al. (1998) Genes Dev. 12, 2831-2841.
    19. Solomon, J.M. et al. (2006) Mol. Cell. Biol. 26, 28-38.
    20. Sakaguchi , K. et al. (2000) J. Biol. Chem. 275, 9278-9283.
    21. Dumaz, N. et al. (1999) FEBS Lett. 463, 312-316.
    Application References

    Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know !

    Companion Products

    For Research Use Only. Not For Use In Diagnostic Procedures.

    风险提示:丁香通仅作为第三方平台,为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全,合理判断,谨慎选购商品,商家和用户对交易行为负责。对于医疗器械类产品,请先查证核实企业经营资质和医疗器械产品注册证情况。

    图标技术资料

    暂无技术资料 索取技术资料

    同类产品报价

    产品名称
    产品价格
    公司名称
    报价日期
    询价
    美国CST中国公司(丁香通商铺)
    2024年08月22日询价
    ¥3662
    北京智杰方远科技有限公司
    2025年07月08日询价
    ¥3662
    上海瑶韵生物科技有限公司
    2025年05月19日询价
    ¥1500
    爱必信(上海)生物科技有限公司
    2025年05月17日询价
    ¥1650
    上海沪震实业有限公司
    2025年06月25日询价
    Phospho-p53 (Thr18) Antibody
    询价